海正药业：关于获得药品补充申请批准通知书的公告

Core Viewpoint - The company, Haizheng Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application for Everolimus tablets, adding a new 2.5mg specification to the already approved 5mg version [1] Group 1 - The company announced the approval of a new specification for Everolimus tablets, which is based on the previously approved 5mg version [1] - The approval notification includes the drug's registration number: Guoyao Zhunzi H20253002 [1]